In summary, we found genetic variants within genes of the SLC and ABC transporter families as risk markers for high-grade hematologic adverse events risk from chemotherapeutic treatment of ALL in Mexican children, as well as other protective variants. The gene discussed is ABCG2; the disease is acute lymphoblastic leukemia.